Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study of the safety, tolerability, pharmacokinetics (measurement of drug levels in the blood), and intraocular pressure lowering effects of OPA-6566 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Acucela Inc.; Kubota Vision Inc.
• Collaborator: Otsuka Pharmaceutical Co., Ltd.
• Treatments: Latanoprost; Ophthalmic Solutions

Criteria

Inclusion Criteria:

• diagnosis of bilateral primary open-angle glaucoma

• diagnosis of ocular hypertension as defined in the protocol

Exclusion Criteria:

• any form of glaucoma other than primary open-angle glaucoma in either eye

• other ocular conditions as defined by the protocol